Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Holding AKBA?
Track your performance easily
AKBA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.78 - $2.48
Previous Close$1.35
Volume847.56K
Average Volume (3M)2.75M
Market Cap
$283.89M
Enterprise Value$288.72M
Total Cash (Recent Filing)$39.50M
Total Debt (Recent Filing)$44.33M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 07, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding210,288,210
10 Day Avg. Volume1,378,293
30 Day Avg. Volume2,746,246
Standard Deviation0.31
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-8.44
Price to Sales (P/S)1.65
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda-35.83
Forecast
1Y Price Target
$6.25Price Target Upside356.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Akebia Therapeutics News
PremiumPre-Earnings
Is AKBA a Buy, Before Earnings?
PremiumCompany Announcements
Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
PremiumCompany Announcements
Akebia Therapeutics Welcomes New CFO and Financial StrategistOwnership Overview
5.75% Insiders
8.92% Mutual Funds
13.92% Other Institutional Investors
71.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.78 and its highest was $2.48 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.032.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.06.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 210,288,210 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went up 7.207%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 59K.
---
Akebia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.25 (356.20% Upside)
$6.25 (356.20% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 28.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.21%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AKBA Earnings Call
Q2 2024
0:00 / 0:00
---
AKBA Stock 12 Month Forecast
Average Price Target
$6.25
▲(356.20% Upside)
Technical Analysis
Corcept Therapeutics
―
Karyopharm Therapeutics
―
Amneal Pharmaceuticals
―
Atea Pharmaceuticals
―
Best Analysts Covering AKBA
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-26.89%
reiterated a buy rating 14 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -26.89% per trade.
---